Table 1 Exogenous OLDA administration modulates circulating cytokines and chemokines during acute inflammation
Inflammatory mediator (mean ± SD) | LPS + vehicle | LPS + OLDA | P (Mann–Whitney) |
|---|---|---|---|
IL-1β (pg/ml) | 101 ± 44 | 40 ± 29 | 0.0005χ |
IL-2 (pg/ml) | 9.3 ± 4.7 | 6.6 ± 2 | 0.04χ |
IL-4 (pg/ml) | 1.9 ± 0.24 | 1.7 ± 0.28 | 0.06 |
IL-5 (pg/ml) | 29 ± 6.1 | 15 ± 8.4 | 0.0003χ |
IL-6 (ng/ml) | 927 ± 26 | 477 ± 196 | < 0.0001χ |
IL-9 (pg/ml) | 165 ± 26 | 60 ± 28 | < 0.0001χ |
IL-10 (ng/ml) | 2.1 ± 0.5 | 13 ± 7.9 | < 0.0001θ |
IL-12p70 (pg/ml) | 26 ± 4.7 | 19 ± 1.8 | 0.0001χ |
IL-13 (pg/ml) | 4.7 ± 1.1 | 3.6 ± 0.32 | 0.003 χ |
IL-17A (pg/ml) | 4.4 ± 2 | 3.4 ± 1.2 | 0.26 |
IL-18 (ng/ml) | 2.4 ± 0.17 | 2.2 ± 0.15 | 0.06 |
IL-22 (ng/ml) | 19 ± 7 | 2.8 ± 2.3 | < 0.0001χ |
IL-23 (pg/ml) | 21 ± 16 | 15 ± 17 | 0.0158χ |
IL-27 (pg/ml) | 100 ± 29 | 41 ± 22 | < 0.0001χ |
GM-CSF (pg/ml) | 22 ± 2.9 | 15 ± 1.8 | < 0.0001χ |
TNF-α (ng/ml) | 1.1 ± 0.33 | 0.61 ± 0.13 | < 0.0001χ |
IFN-γ (pg/ml) | 13 ± 4.7 | 8.6 ± 1.7 | 0.01χ |
MCP-1/CCL-2 (ng/ml) | 91.3 ± 22 | 55.7 ± 19 | < 0.0001χ |
MIP-1α/CCL-3 (ng/ml) | 1.2 ± 0.2 | 0.75 ± 0.2 | < 0.0001χ |
MIP-1β/CCL-4 (ng/ml) | 5.8 ± 1.3 | 5.1 ± 2 | 0.52 |
RANTES/CCL-5 (ng/ml) | 0.8 ± 0.17 | 0.4 ± 0.15 | < 0.0001χ |
MCP-3/CCL-7 (ng/ml) | 1.2 ± 0.16 | 0.99 ± 0.1 | 0.0028χ |
Eotaxin/CCL-11 (ng/ml) | 1 ± 0.12 | 0.81 ± 0.09 | < 0.0001χ |
Gro-α/CXCL-1 (ng/ml) | 12 ± 5.7 | 6.1 ± 4.3 | 0.016χ |
IP-10/CXCL-10 (pg/ml) | 476 ± 37 | 359 ± 75 | < 0.0001χ |